Global Startups Insights
Lets your startup
Funding News, New York, USA Startup Funding News

Polyphron Raises $20M in Seed Round

September 17, 2026
By
Loren Baker
Polyphron Raises $20M in Seed Round

Polyphron, a New York-based company developing artificial human biology for drug development, has raised $20 million in seed funding.

The round was led by Quiet Capital, with participation from Gradient, Haystack, and Compound.

Polyphron is combining AI, stem-cell biology, automated tissue manufacturing, and simulation technology to help researchers test drug and biological hypotheses using human tissue.

The company says AI systems are becoming better at generating drug candidates and experimental ideas, but testing those ideas in human biology remains slow and expensive. Animal studies and clinical trials can take significant time, while traditional laboratory and computer models may not fully capture the complex behavior of human tissues.

Polyphron is developing what it calls Tissue Testing Environments, which combine physical human tissues with AI-based simulations.

Its platform has two main components: the Tissue Foundry, an automated system that grows human micro-tissues from stem cells, and the Tissue World Model, an AI simulation system trained on data from living tissues.

“We back founders who are building infrastructure that changes what’s economically possible, not just what’s scientifically interesting,” said Michael Bloch of Quiet Capital. “If you can make tissue a manufacturable, testable unit at scale, you change the economics of drug development. Polyphron is applying that infrastructure mindset to human biology.”

The company’s first focus is cardiac tissue, which is already being produced across multiple donor lines. Polyphron plans to expand into liver tissue this year to study drug metabolism and liver toxicity.

The long-term goal is to use these systems to predict how treatments may affect different people before clinical trials, including potential toxicity and which patients may respond to a treatment.

Polyphron was co-founded by Osman and Fabio Boniolo, Ph.D., who previously worked at Dana-Farber Cancer Institute, the Broad Institute, and Harvard Medical School. Vinh Q. Tran, formerly a post-training and self-improvement researcher for Gemini at Google DeepMind, recently joined as co-founder and Chief AI Scientist.

“AI will not cure all diseases without a verification layer. The cost of producing another new therapeutic hypothesis or intervention in many modalities could soon approach zero but this will not lead to cures until something can answer, ‘What will this intervention actually do to a heterogeneous human biological system over time?’” said Matthew Osman, Polyphron’s co-founder and CEO. “The missing piece is a scalable environment where models can test predictions against living human biology – and our bet is that tissue is the right abstraction layer for this scalable environment.”

The company also includes George Pilitsis, Chief Operating Officer, who previously founded and scaled the Datapoints product line at Ginkgo Bioworks.

Recommended Stories for You